Business of Biosimilars Conference

Event Overview

Co-Located Events

Central Labs
Clinical Trials

Welcome

The Business of Biosimilars Conference

New Keynote Speaker Confirmed

Ajaz S.Hussain, Ph.D, Vice President Biological System, PMI
Wednesday, September 22, 2010 – 1:30PM
Will Biosimilars be a Driver for Innovation and Continual Improvement in Biopharmaceutical Manufacturing?
Download the updated agenda, Click Here

The biopharmaceutical paradigm is changing.
How do you ensure your economic success?

IIR’s 2nd Annual Business of Biosimilars conference delivers effective strategies to navigate scientific, regulatory, economic, and legal challenges you face to remain competitive in commercializing your biosimilar portfolio in the United States and abroad.

Embrace change to move forward.

At the 2010 Biosimilars conference you will:

  • Navigate worldwide regulatory and legislative issues
  • Build strategic partnerships with emerging markets
  • Adopt effective IP and patent protection strategies for biosimilars
  • Evaluate scientific implications of biosimilars to ensure safety, quality, and efficacy
  • Manage risk and make investment decisions to ensure ROI
  • Obtain branding strategies to differentiate a product on the market
  • Negotiate pricing and reimbursement strategies with government and payers
  • Profit from practical lessons in Canada and Europe’s regulatory policies and market experience
  • Discuss evolving consumer and physician perspectives on biosimilars

Testimonials from the 2009 Event

“I think the conference was an excellent, balanced overview of the key issues with thoughtful and knowledgeable speakers and participants. This is certainly going to grow in interest as a relevant issue in the health care area as we move toward Congressional passage of a biosimilar pathway.”

Henry G. Grabowski, PhD, Professor of Economics & Director of the Program in Pharmaceuticals & Health Economics, Duke University

“This was a great conference. The speakers were outstanding. I appreciate all the work you and your staff did to get all these great industry experts there and willing to speak.”

Jim Verzuh, Director of Marketing, BioScience Laboratories, Inc.

Speakers

  • John Purves, MD, Head of Quality of Medicines, European Medicines Agency
  • Charles Di Liberti, former Vice President, Scientific Affairs, Barr Laboratories
  • Elizabeth Jex, Office of Policy Planning, Federal Trade Commission
  • Cole Pinnow, Vice President of Global Marketing, Hospira
  • Mark McCamish, Head Global Biopharmaceutical Development, Sandoz International GmbH
  • Anthony Ridgway, Senior Regulatory Scientist, Health Canada
  • Gillian Woollett, Chief Scientist, Engel & Novitt
  • Peter Pitts, President, Center for Medicine in the Public Interest